Prilosec To Remain Rx Pending OTC Label Revisions, Patient Study – Cmte.
Executive Summary
AstraZeneca/Procter & Gamble's Prilosec should remain a prescription-only medication pending revisions to the proposed OTC label, a joint FDA advisory committee suggested June 21
You may also be interested in...
Prilosec OTC Switch Set For Early 2003 Following FDA “Approvable” Letter
AstraZeneca's OTC switch for Prilosec (omeprazole) will wait until 2003 after receipt of an "approvable" letter from FDA
Prilosec OTC Switch Set For Early 2003 Following FDA “Approvable” Letter
AstraZeneca's OTC switch for Prilosec (omeprazole) will wait until 2003 after receipt of an "approvable" letter from FDA
Prilosec OTC Review: Two Advisory Cmte. Members Weigh In Without Voting
An upcoming publication by FDA's Gastrointestinal Drugs Advisory Committee chairman will suggest a potential link between proton pump inhibitor therapy and the proliferation of pre-existing esophageal adenocarcinoma